127 related articles for article (PubMed ID: 2001986)
1. Studies on macrocyclic lactone antibiotics. XIII. Anti-tubulin activity and cytotoxicity of rhizoxin derivatives: synthesis of a photoaffinity derivative.
Kato Y; Ogawa Y; Imada T; Iwasaki S; Shimazaki N; Kobayashi T; Komai T
J Antibiot (Tokyo); 1991 Jan; 44(1):66-75. PubMed ID: 2001986
[TBL] [Abstract][Full Text] [Related]
2. Studies on macrocyclic lactone antibiotics. XI. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues.
Takahashi M; Iwasaki S; Kobayashi H; Okuda S; Murai T; Sato Y; Haraguchi-Hiraoka T; Nagano H
J Antibiot (Tokyo); 1987 Jan; 40(1):66-72. PubMed ID: 3606749
[TBL] [Abstract][Full Text] [Related]
3. Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines.
Tsuruo T; Oh-hara T; Iida H; Tsukagoshi S; Sato Z; Matsuda I; Iwasaki S; Okuda S; Shimizu F; Sasagawa K
Cancer Res; 1986 Jan; 46(1):381-5. PubMed ID: 3753552
[TBL] [Abstract][Full Text] [Related]
4. [Total synthesis of antitumor macrolide, rhizoxin and chemistry of acylsilane].
Nakada M
Yakugaku Zasshi; 1997 Aug; 117(8):486-508. PubMed ID: 9306725
[TBL] [Abstract][Full Text] [Related]
5. Syntheses and bioactivities of macrocyclic paclitaxel bis-lactones.
Liu C; Schilling JK; Ravindra R; Bane S; Kingston DG
Bioorg Med Chem; 2004 Dec; 12(23):6147-61. PubMed ID: 15519159
[TBL] [Abstract][Full Text] [Related]
6. Vermiculin derivatives. Part 1: Synthesis of vermiculin derivatives.
Proksa B; Uhrín D; Adamacová J; Múcková M; Fuska J
Pharmazie; 1993 Oct; 48(10):738-40. PubMed ID: 8265708
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor properties of 3'-(4-morpholinyl) and 3'-(4-methoxy-1-piperidinyl) derivatives of 3'-deaminodaunorubicin.
Mosher CW; Wu HY; Fujiwara AN; Acton EM
J Med Chem; 1982 Jan; 25(1):18-24. PubMed ID: 7086816
[TBL] [Abstract][Full Text] [Related]
8. Intracellular activation and cytotoxic action of RS-1541 against cultured human tumor cells.
Takatori T; Koizumi T; Tokui T; Mitsuhashi Y; Shiraishi A; Tsuruo T
Cancer Chemother Pharmacol; 1995; 35(4):283-90. PubMed ID: 7828270
[TBL] [Abstract][Full Text] [Related]
9. Interaction of rhizoxin with bovine brain tubulin.
Sullivan AS; Prasad V; Roach MC; Takahashi M; Iwasaki S; Ludueña RF
Cancer Res; 1990 Jul; 50(14):4277-80. PubMed ID: 2364385
[TBL] [Abstract][Full Text] [Related]
10. Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent.
Hendriks HR; Plowman J; Berger DP; Paull KD; Fiebig HH; Fodstad O; Dreef-van der Meulen HC; Henrar RE; Pinedo HM; Schwartsmann G
Ann Oncol; 1992 Nov; 3(9):755-63. PubMed ID: 1450065
[TBL] [Abstract][Full Text] [Related]
11. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B.
Hamel E
Pharmacol Ther; 1992; 55(1):31-51. PubMed ID: 1287674
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of angiogenesis by rhizoxin, a microbial metabolite containing two epoxide groups.
Onozawa C; Shimamura M; Iwasaki S; Oikawa T
Jpn J Cancer Res; 1997 Dec; 88(12):1125-9. PubMed ID: 9473728
[TBL] [Abstract][Full Text] [Related]
13. Fluorescent and photoaffinity labeling derivatives of rhizoxin.
Sawada T; Hashimoto Y; Li Y; Kobayashi H; Iwasaki S
Biochem Biophys Res Commun; 1991 Jul; 178(2):558-62. PubMed ID: 1859416
[TBL] [Abstract][Full Text] [Related]
14. Tumor selective effect of RS-1541 (palmitoyl-rhizoxin) in M5076 sarcoma and host tissues in vivo.
Tokui T; Maeda N; Kuroiwa C; Sasagawa K; Inoue T; Kawai K; Ikeda T; Komai T
Pharm Res; 1995 Mar; 12(3):370-5. PubMed ID: 7617523
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
Kuo SC; Lee HZ; Juang JP; Lin YT; Wu TS; Chang JJ; Lednicer D; Paull KD; Lin CM; Hamel E
J Med Chem; 1993 Apr; 36(9):1146-56. PubMed ID: 8387598
[TBL] [Abstract][Full Text] [Related]
16. Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
McLeod HL; Murray LS; Wanders J; Setanoians A; Graham MA; Pavlidis N; Heinrich B; ten Bokkel Huinink WW; Wagener DJ; Aamdal S; Verweij J
Br J Cancer; 1996 Dec; 74(12):1944-8. PubMed ID: 8980394
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and cytostatic activity of the antitumor antibiotic chartreusin derivatives.
Kon K; Sugi H; Tamai K; Ueda Y; Yamada N
J Antibiot (Tokyo); 1990 Apr; 43(4):372-82. PubMed ID: 2351612
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance.
Arioka H; Nishio K; Heike Y; Abe S; Saijo N
J Cancer Res Clin Oncol; 1997; 123(4):195-200. PubMed ID: 9177491
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antitumor activity of novel C-8 ester derivatives of leinamycin.
Kanda Y; Ashizawa T; Kawashima K; Ikeda S; Tamaoki T
Bioorg Med Chem Lett; 2003 Feb; 13(3):455-8. PubMed ID: 12565949
[TBL] [Abstract][Full Text] [Related]
20. N-salicylidene derivatives of pirarubicin.
Ajito K; Ikeda D; Komuro K; Nosaka C; Wako N; Kondo S; Takeuchi T
J Antibiot (Tokyo); 1989 Jul; 42(7):1133-44. PubMed ID: 2753818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
